Remove Clinical Trials Remove Collective Remove Events Remove Sleep
article thumbnail

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

article thumbnail

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Cannabis Law Report

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine. This stage lasts for 8 to 20 hours.

History 119
article thumbnail

Why nurses must be involved in cannabis patient care

The Cannigma

My partner, who was diagnosed with Crohn’s Disease at the age of 19, was able to improve his quality of life with cannabis by managing his nausea, poor quality sleep, gut motility, appetite, pain, and anxiety with a single substance. The more I read about it, the more I became fascinated with the chemistry and potential of cannabis.

Patients 145
article thumbnail

SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study

Cannabis Law Report

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. Logo – [link]. SOURCE SciSparc Ltd.

article thumbnail

A Hidden Origin Story of the CBD Craze

SMPL

We were talking about, ‘What can we do with this?’ ” recalled Samantha Miller, who hosted the event at her split-level house, wedged between redwoods and a creek below. fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex. But the research wasn’t enough. And because of public demand, the F.D.A.

CBD 40
article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

Data collection. Less frequent were references to multiple sclerosis, anxiety and depression, sleep, and HIV. It is unclear whether doctors are feeling completely reassured by laboratory and clinical trial research into medicinal cannabis. 23), followed by adverse events ( n ?=?15) Full size image. Contributions.